Successful treatment with alectinib after crizotinib-induced esophageal ulceration

Lung Cancer

Volumn 88, Issue 3, 2015, Pages 349-351

  Yoneshima, Yasuto ^a   Okamoto, Isamu ^a,b   Takano, Tomotsugu ^a   Enokizu, Aimi ^a   Iwama, Eiji ^a,c   Harada, Taishi ^a   Takayama, Koichi ^a   Nakanishi, Yoichi ^a,b  

^a KYUSHU UNIVERSITY   (Japan)

^b KYUSHU UNIVERSITY HOSPITAL   (Japan)

^c KYUSHU UNIVERSITY   (Japan)

Author keywords

Alectinib; Anaplastic lymphoma kinase (ALK); Crizotinib; Esophageal ulceration; Non small cell lung cancer (NSCLC)

Indexed keywords

ALECTINIB; CRIZOTINIB; CARBAZOLE DERIVATIVE; PIPERIDINE DERIVATIVE; PROTEIN KINASE INHIBITOR; PYRAZOLE DERIVATIVE; PYRIDINE DERIVATIVE;

ADULT; ARTICLE; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CASE REPORT; CLINICAL FEATURE; COMPUTER ASSISTED TOMOGRAPHY; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG WITHDRAWAL; DYSPHAGIA; ESOPHAGOSCOPY; ESOPHAGUS ULCER; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; INFLAMMATION; LUNG ADENOCARCINOMA; MIDDLE AGED; ODYNOPHAGIA; PRIORITY JOURNAL; TREATMENT OUTCOME; CARCINOMA, NON-SMALL-CELL LUNG; CHEMICALLY INDUCED; COMPLICATION; ENDOSCOPE; ESOPHAGEAL DISEASES; LUNG NEOPLASMS; ULCER;

CARBAZOLES; CARCINOMA, NON-SMALL-CELL LUNG; ENDOSCOPES; ESOPHAGEAL DISEASES; FEMALE; HUMANS; LUNG NEOPLASMS; MIDDLE AGED; PIPERIDINES; PROTEIN KINASE INHIBITORS; PYRAZOLES; PYRIDINES; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME; ULCER;

EID: 84929506043     PISSN: 01695002     EISSN: 18728332     Source Type: Journal    
DOI: 10.1016/j.lungcan.2015.03.012     Document Type: Article

References (8)

1. Kwak E.L., Bang Y.J., Camidge D.R., Shaw A.T., Solomon B., Maki R.G., et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med 2010, 363:1693-1703.
2. Camidge D.R., Bang Y.J., Kwak E.L., Iafrate A.J., Varella-Garcia M., Fox S.B., et al. Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study. Lancet Oncol 2012, 13:1011-1019.
3. Srivastava N., VanderLaan P.A., Kelly C.P., Costa D.B. Esophagitis: a novel adverse event of crizotinib in a patient with ALK-positive non-small-cell lung cancer. J Thorac Oncol 2013, 8:e23-e24.
4. Park J., Yoshida K., Kondo C., Shimizu J., Horio Y., Hijioka S., et al. Crizotinib-induced esophageal ulceration: a novel adverse event of crizotinib. Lung Cancer 2013, 81:495-496.
5. Seto T., Kiura K., Nishio M., Nakagawa K., Maemondo M., Inoue A., et al. (RO5424802) for patients with ALK-rearranged advanced non-small-cell lung cancer (AF-001JP study): a single-arm, open-label, phase 1-2 study. Lancet Oncol 2013, 14:590-598.
6. Solomon B.J., Mok T., Kim D.W., Wu Y.L., Nakagawa K., Mekhail T., et al. First-line crizotinib versus chemotherapy in ALK-positive lung cancer. N Engl J Med 2014, 371:2167-2177.
7. Baatar D., Jones M.K., Pai R., Kawanaka H., Szabo I.L., Moon W.S., et al. Selective cyclooxygenase-2 blocker delays healing of esophageal ulcers in rats and inhibits ulceration-triggered c-Met/hepatocyte growth factor receptor induction and extracellular signal-regulated kinase 2 activation. Am J Pathol 2002, 160:963-972.
8. Sakamoto H., Tsukaguchi T., Hiroshima S., Kodama T., Kobayashi T., Fukami T.A., et al. a selective ALK inhibitor capable of blocking the resistant gatekeeper mutant. Cancer Cell 2011, 19:679-690.